While additive or synergistic anti-tumor effects were not observed in concert with anti-PD-L1 or anti-CTLA-4 blockade, future detailed studies are warranted to explore combinations with other immunotherapies, such as other ICIs (alone or in combination), vaccines, and/or cell therapies, for potentially enhanced therapeutic benefit. Here, CTLA4 is linked to neoplasm.